Protagonist Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
PTGX$136.26+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| · 2024 · 2023 | ||||||
| Cash Flows from Operating Activities · · · | ||||||
| Net income (loss) | | $207,340 | | $(33,725) | ||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | | | | | |
| Stock-based compensation | | | 9,352 | | | 7,584 |
| Operating lease right-of-use asset amortization | | | 584 | | | 584 |
| Accretion of discount on marketable securities | | | (1,615) | | | (1,255) |
| Depreciation | | | 236 | | | 248 |
| Other | | | — | | | 194 |
| Changes in operating assets and liabilities: | | | | | | |
| Receivable from collaboration partner | | | (290,043) | | | (41) |
| Prepaid expenses and other assets | | | (915) | | | 787 |
| Accounts payable | | | 2,825 | | | 381 |
| Payable to collaboration partner | | | — | | | (47) |
| Accrued expenses and other payables | | | (2,870) | | | (8,383) |
| Deferred revenue | | | 45,047 | | | — |
| Income taxes payable | | | 3,326 | | | — |
| Operating lease liability | | | (696) | | | (674) |
| Net cash used in operating activities | | | (27,429) | | | (34,347) |
| Cash Flows from Investing Activities | | | | | | |
| Purchase of marketable securities | | | (65,671) | | | (28,060) |
| Proceeds from maturities of marketable securities | | | 71,984 | | | 37,896 |
| Purchases of property and equipment | | | (242) | | | (10) |
| Net cash provided by investing activities | | | 6,071 | | | 9,826 |
| Cash Flows from Financing Activities | | | | | | |
| Proceeds from at-the-market offering, net of issuance costs | | | — | | | 24,302 |
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | | | 7,799 | | | 2,261 |
| Tax withholding payments related to net settlement of restricted stock units | | | (600) | | | (100) |
| Net cash provided by financing activities | | | 7,199 | | | 26,463 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | | | (14,159) | | | 1,942 |
| Cash, cash equivalents and restricted cash, beginning of period | | 186,952 | | 125,969 | ||
| Cash, cash equivalents and restricted cash, end of period | | $172,793 | | $127,911 | ||
| Supplemental Disclosure of Non-Cash Financing and Investing Information: | | | | | | |
| Purchases of property and equipment in accounts payable and accrued liabilities | | $45 | | $15 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.